Opiant Pharmaceuticals, Inc. Announces Establishment of Audit, Compensation and Nominating and Corporate Governance Committees
31 janv. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...
Opiant Pharmaceuticals, Inc. Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray
26 janv. 2017 11h23 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...
Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals
11 janv. 2017 08h00 HE
|
Opiant Pharmaceuticals, Inc.
- Plans to Initiate Phase 2 Study in Bulimia Nervosa - - Company to Pursue Uplisting to a Major Stock Exchange - SANTA MONICA, Calif., Jan. 11, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals,...
Opiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN® Nasal Spray and Heroin Vaccine Development
09 janv. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...
Opiant Pharmaceuticals, Inc., Reports Fiscal First Quarter 2017 Financial Results and Provides Corporate Update
16 déc. 2016 08h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...
Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization
15 déc. 2016 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...
Opiant Pharmaceuticals, Inc. Announces Appointment of Thomas T. Thomas to Board of Directors
10 nov. 2016 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...
Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
31 oct. 2016 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals, Inc. Licenses Heroin Vaccine From Walter Reed Army Institute of Research and National Institute on Drug Abuse
28 oct. 2016 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for Narcan® Nasal Spray Patent
27 oct. 2016 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance...